Efficacy of sorafenib, a multi-tyrosine kinase inhibitor, in an adenoid cystic carcinoma metastatic to the lung: Case report and review of literature

Journal of Medical Case Reports

Volumn 5, Issue , 2011, Pages

  Dammrich, Daniel J ^a   Santos, Edgardo S ^a   Raez, Luis E ^a  

^a UNIVERSITY OF MIAMI   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; PLATELET DERIVED GROWTH FACTOR; RAF PROTEIN; SORAFENIB;

ADENOID CYSTIC CARCINOMA; ADULT; ANGIOGENESIS; CANCER RADIOTHERAPY; CANCER SURGERY; CASE REPORT; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; HAND PARESTHESIA; HUMAN; HUMAN TISSUE; LUNG BIOPSY; LUNG METASTASIS; MAXILLA SINUSITIS; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; REVIEW; SKIN EXFOLIATION; SKIN REDNESS; SKIN SWELLING; THROMBOCYTOPENIA;

EID: 80053365990     PISSN: None     EISSN: 17521947     Source Type: Journal    
DOI: 10.1186/1752-1947-5-483     Document Type: Review

References (8)

1. Adenoid cystic carcinoma of the head and neck: a review. Bradley PJ, Curr Opin Otolaryngol Head Neck Surg 2004 12 2 127 132 10.1097/00020840-200404000- 00013 15167050 (Pubitemid 38420202)
2. An update on the systemic therapy of malignant salivary gland cancers: role of chemotherapy and molecular targeted agents. Agulnik M, Siu LL, Curr Med Chem Anticancer Agents 2004 4 6 543 551 10.2174/1568011043352641 15579019 (Pubitemid 39406266)
3. New guidelines to evaluate the response to treatment in solid tumors. Therasse T, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG, J Natl Cancer Inst 2000 92 3 205 216 10.1093/jnci/92.3.205 10655437 (Pubitemid 30099779)
4. Salivary gland adenoid cystic carcinoma: a review of chemotherapy and molecular therapies. Dodd RL, Slevin NJ, Oral Oncol 2006 42 8 759 769 10.1016/j.oraloncology.2006.01.001 16757203 (Pubitemid 44307768)
5. Chemoradiotherapy for adenoid cystic carcinoma: preliminary results of an organ sparing approach. Haddad RI, Posner MR, Busse PM, Norris CM Jr, Goguen LA, Wirth LJ, Blinder R, Krane JF, Tishler RB, Am J Clin Oncol 2006 29 2 153 157 10.1097/01.coc.0000203756.36866.17 16601434 (Pubitemid 44270955)
6. Imatinib mesylate in patients with adenoid cystic cancers of the salivary glands expression c-kit: a Princess Margaret Hospital Phase II Consortium Study. Hotte SJ, Winquist EW, Lamont E, MacKenzie M, Vokes E, Chen EX, Brown S, Pond GR, Murgo A, Siu LL, J Clin Oncol 2005 23 3 585 590 15659505 (Pubitemid 46224236)
7. Unexpected rapid progression of metastatic adenoid cystic carcinoma during treatment with imatinib mesylate. Lin CH, Yen RF, Jeng YM, Tzen CY, Hsu C, Hong RL, Head Neck 2005 27 12 1022 1027 10.1002/hed.20274 16265655 (Pubitemid 41705578)
8. Herceptin in patients with advanced or metastatic salivary gland carcinomas. A phase II study. Haddad R, Colevas AD, Krane JF, Cooper D, Glisson B, Amrein PC, Weeks L, Costello R, Posner M, Oral Oncol 2003 39 7 724 727 10.1016/S1368-8375(03)00097-6 12907212 (Pubitemid 36930120)